Enasidenib, the first FDA-approved IDH2-mutant inhibitor, received approval in 2017 after positive results from a single-arm trial on relapsed or refractory AML patients with IDH2 mutations (NCT01915498). This evidence concerns the gene IDH2 and acute myeloid leukemia.